Watch Demo

Global Oligonucleotide Synthesis Industry

Global Oligonucleotide Synthesis Industry

  • Publish Date:January 2023

  • Number of Pages:194

  • Report ID:5799261

  • Format:PDF

  • Publisher:Global Industry Analysts

$ 5450

Summary

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Oligonucleotide Synthesis Market to Reach $19.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Oligonucleotide Synthesis estimated at US$6.1 Billion in the year 2022, is projected to reach a revised size of US$19.9 Billion by 2030, growing at a CAGR of 15.9% over the analysis period 2022-2030. Oligonucleotide-Based Drugs, one of the segments analyzed in the report, is projected to record a 17.6% CAGR and reach US$8.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Synthesized Oligonucleotides segment is readjusted to a revised 15.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 21.5% CAGR

The Oligonucleotide Synthesis market in the U.S. is estimated at US$1.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 13.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.1 Billion by the year 2030.

Select Competitors (Total 41 Featured)
- ATDBio Ltd.
- Bio-Synthesis Inc.
- Eurogentec
- GE Healthcare Life Sciences
- GeneDesign, Inc.
- GenScript Biotech Corporation
- Integrated DNA Technologies (IDT), Inc.
- LGC Biosearch Technologies
- Merck KgaA
- Nitto Denko Avecia Inc.
- Thermo Fisher Scientific, Inc.

Table of contents

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Oligonucleotide Synthesis Market Set for a Steady Growth
Oligonucleotide Synthesis Market by End-use: 2018
Oligonucleotide Synthesis Market Breakdown by Geographic
Region: 2018
Oligonucleotide Synthesis - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Growing Demand for Oligonucleotide-based Drugs to Boost the
Oligonucleotide Synthesis Market
Increased Pharma R&D to Spur the Market Growth
FDA-Approved Oligonucleotide-based Drugs Promise Huge Potential
for Market Growth
Recent Approval of Exondys 51 and Nusinersen Aids in Treatment
of Inherited Diseases
Oligonucleotide Drugs Aid Effective Treatment of
Neurodegenerative Disorders
Inotersen - The Second FDA Approved Drug for Polyneuropathy,
Following Onpattro
Market Outlook and Advancements in Antisense Drugs

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Oligonucleotide Synthesis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Oligonucleotide
Synthesis by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Diagnostic Laboratories by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Diagnostic Laboratories by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Diagnostic Laboratories
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 7: World Oligonucleotide Synthesis Market Analysis of
Annual Sales in US$ Million for Years 2014 through 2030

Table 8: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 9: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 10: World 16-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for
Pharma & Biotech Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 12: World Historic Review for Pharma & Biotech Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 13: World 16-Year Perspective for Pharma & Biotech
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 14: World Recent Past, Current & Future Analysis for
Oligonucleotide-Based Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 15: World Historic Review for Oligonucleotide-Based Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 16: World 16-Year Perspective for Oligonucleotide-Based
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 17: World Recent Past, Current & Future Analysis for
Synthesized Oligonucleotides by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 18: World Historic Review for Synthesized
Oligonucleotides by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 19: World 16-Year Perspective for Synthesized
Oligonucleotides by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 20: World Recent Past, Current & Future Analysis for
Reagents by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 21: World Historic Review for Reagents by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 22: World 16-Year Perspective for Reagents by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 23: World Recent Past, Current & Future Analysis for
Equipment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 24: World Historic Review for Equipment by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 25: World 16-Year Perspective for Equipment by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 26: World Recent Past, Current & Future Analysis for
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 27: World Historic Review for Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 28: World 16-Year Perspective for Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 29: World Recent Past, Current & Future Analysis for
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 30: World Historic Review for Diagnostics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 31: World 16-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 32: World Recent Past, Current & Future Analysis for
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 33: World Historic Review for Research by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 34: World 16-Year Perspective for Research by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 35: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 36: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 37: World 16-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 38: USA Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 39: USA Historic Review for Oligonucleotide Synthesis by
Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 40: USA 16-Year Perspective for Oligonucleotide Synthesis
by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 41: USA Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 42: USA Historic Review for Oligonucleotide Synthesis by
Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 43: USA 16-Year Perspective for Oligonucleotide Synthesis
by Application - Percentage Breakdown of Value Sales for
Therapeutics, Diagnostics and Research for the Years 2014, 2023 &
2030

Table 44: USA Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Oligonucleotide Synthesis by
End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech
Companies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 46: USA 16-Year Perspective for Oligonucleotide Synthesis
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Pharma & Biotech Companies and Other
End-Uses for the Years 2014, 2023 & 2030

CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: Canada Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 49: Canada 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 50: Canada Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 51: Canada Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 52: Canada 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 53: Canada Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 54: Canada Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 55: Canada 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

JAPAN
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 56: Japan Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 57: Japan Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 58: Japan 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 59: Japan Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 60: Japan Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 61: Japan 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 62: Japan Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: Japan Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 64: Japan 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

CHINA
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 65: China Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 66: China Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 67: China 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 68: China Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 69: China Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 70: China 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 71: China Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: China Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 73: China 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

EUROPE
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 74: Europe Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 75: Europe Historic Review for Oligonucleotide Synthesis
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 76: Europe 16-Year Perspective for Oligonucleotide
Synthesis by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2014, 2023 & 2030

Table 77: Europe Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 78: Europe Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 79: Europe 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 80: Europe Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 81: Europe Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 82: Europe 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 83: Europe Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 84: Europe Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 85: Europe 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

FRANCE
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 86: France Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: France Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 88: France 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 89: France Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 90: France Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 91: France 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 92: France Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: France Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 94: France 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

GERMANY
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 95: Germany Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 96: Germany Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 97: Germany 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 98: Germany Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 99: Germany Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 100: Germany 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 101: Germany Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 102: Germany Historic Review for Oligonucleotide
Synthesis by End-Use - Hospitals, Diagnostic Laboratories,
Pharma & Biotech Companies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 103: Germany 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

ITALY
Table 104: Italy Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 105: Italy Historic Review for Oligonucleotide Synthesis
by Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 106: Italy 16-Year Perspective for Oligonucleotide
Synthesis by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 107: Italy Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 108: Italy Historic Review for Oligonucleotide Synthesis
by Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 109: Italy 16-Year Perspective for Oligonucleotide
Synthesis by Application - Percentage Breakdown of Value Sales
for Therapeutics, Diagnostics and Research for the Years 2014,
2023 & 2030

Table 110: Italy Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 111: Italy Historic Review for Oligonucleotide Synthesis
by End-Use - Hospitals, Diagnostic Laboratories, Pharma &
Biotech Companies and Other End-Uses Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 112: Italy 16-Year Perspective for Oligonucleotide
Synthesis by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies
and Other End-Uses for the Years 2014, 2023 & 2030

UNITED KINGDOM
Oligonucleotide Synthesis Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 113: UK Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Product - Oligonucleotide-Based
Drugs, Synthesized Oligonucleotides, Reagents and Equipment -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 114: UK Historic Review for Oligonucleotide Synthesis by
Product - Oligonucleotide-Based Drugs, Synthesized
Oligonucleotides, Reagents and Equipment Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 115: UK 16-Year Perspective for Oligonucleotide Synthesis
by Product - Percentage Breakdown of Value Sales for
Oligonucleotide-Based Drugs, Synthesized Oligonucleotides,
Reagents and Equipment for the Years 2014, 2023 & 2030

Table 116: UK Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by Application - Therapeutics,
Diagnostics and Research - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 117: UK Historic Review for Oligonucleotide Synthesis by
Application - Therapeutics, Diagnostics and Research Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 118: UK 16-Year Perspective for Oligonucleotide Synthesis
by Application - Percentage Breakdown of Value Sales for
Therapeutics, Diagnostics and Research for the Years 2014, 2023 &
2030

Table 119: UK Recent Past, Current & Future Analysis for
Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic
Laboratories, Pharma & Biotech Companies and Other End-Uses -

Please contact our Customer Support Center to get the complete Table of Contents

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.